Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Guthy DA"'
Publikováno v:
BMC Cancer, Vol 11, Iss 1, p 24 (2011)
Abstract Background The JAK2V617F mutation plays a major role in the pathogenesis of myeloproliferative neoplasms and is found in the vast majority of patients suffering from polycythemia vera and in roughly every second patient suffering from essent
Externí odkaz:
https://doaj.org/article/a9ad6b3c85974c899fb74699af381a93
Autor:
Lorthiois E; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Gerspacher M; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Beyer KS; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Vaupel A; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Leblanc C; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Stringer R; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Weiss A; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Wilcken R; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Guthy DA; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Lingel A; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Bomio-Confaglia C; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Machauer R; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Rigollier P; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Ottl J; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Arz D; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Bernet P; Novartis Pharma AG, BaselCH-4056, Switzerland., Desjonqueres G; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Dussauge S; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Kazic-Legueux M; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Lozac'h MA; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Mura C; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Sorge M; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Todorov M; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Warin N; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Zink F; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Voshol H; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Zecri FJ; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts02139, United States., Sedrani RC; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Ostermann N; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Brachmann SM; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Cotesta S; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2022 Dec 22; Vol. 65 (24), pp. 16173-16203. Date of Electronic Publication: 2022 Nov 18.
Autor:
Fairhurst RA; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Furet P; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Imbach-Weese P; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Stauffer F; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Rueeger H; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., McCarthy C; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Ripoche S; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Oswald S; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Arnaud B; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Jary A; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Maira M; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Schnell C; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Guthy DA; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Wartmann M; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Kiffe M; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Desrayaud S; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Blasco F; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Widmer T; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Seiler F; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Gutmann S; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland., Knapp M; Novartis Institutes for BioMedical Research, Emeryville, California 94608, United States., Caravatti G; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2022 Jun 23; Vol. 65 (12), pp. 8345-8379. Date of Electronic Publication: 2022 May 02.
Autor:
Weiss A; Novartis Institutes for BioMedical Research, Basel, Switzerland., Lorthiois E; Novartis Institutes for BioMedical Research, Basel, Switzerland., Barys L; Novartis Institutes for BioMedical Research, Basel, Switzerland., Beyer KS; Novartis Institutes for BioMedical Research, Basel, Switzerland., Bomio-Confaglia C; Novartis Institutes for BioMedical Research, Basel, Switzerland., Burks H; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Chen X; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey., Cui X; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey., de Kanter R; Novartis Institutes for BioMedical Research, Basel, Switzerland., Dharmarajan L; Novartis Institutes for BioMedical Research, Basel, Switzerland., Fedele C; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Gerspacher M; Novartis Institutes for BioMedical Research, Basel, Switzerland., Guthy DA; Novartis Institutes for BioMedical Research, Basel, Switzerland., Head V; Novartis Institutes for BioMedical Research, Basel, Switzerland., Jaeger A; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Núñez EJ; Novartis Institutes for BioMedical Research, Basel, Switzerland., Kearns JD; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Leblanc C; Novartis Institutes for BioMedical Research, Basel, Switzerland., Maira SM; Novartis Institutes for BioMedical Research, Basel, Switzerland., Murphy J; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Oakman H; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Ostermann N; Novartis Institutes for BioMedical Research, Basel, Switzerland., Ottl J; Novartis Institutes for BioMedical Research, Basel, Switzerland., Rigollier P; Novartis Institutes for BioMedical Research, Basel, Switzerland., Roman D; Novartis Institutes for BioMedical Research, Basel, Switzerland., Schnell C; Novartis Institutes for BioMedical Research, Basel, Switzerland., Sedrani R; Novartis Institutes for BioMedical Research, Basel, Switzerland., Shimizu T; National Cancer Center Hospital, Tokyo, Japan., Stringer R; Novartis Institutes for BioMedical Research, Basel, Switzerland., Vaupel A; Novartis Institutes for BioMedical Research, Basel, Switzerland., Voshol H; Novartis Institutes for BioMedical Research, Basel, Switzerland., Wessels P; Novartis Pharma AG, Basel, Switzerland., Widmer T; Novartis Pharma AG, Basel, Switzerland., Wilcken R; Novartis Institutes for BioMedical Research, Basel, Switzerland., Xu K; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey., Zecri F; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Farago AF; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Cotesta S; Novartis Institutes for BioMedical Research, Basel, Switzerland., Brachmann SM; Novartis Institutes for BioMedical Research, Basel, Switzerland.
Publikováno v:
Cancer discovery [Cancer Discov] 2022 Jun 02; Vol. 12 (6), pp. 1500-1517.
Autor:
Jeay S, Gaulis S, Ferretti S, Bitter H, Ito M, Valat T, Murakami M, Ruetz S, Guthy DA, Rynn C, Jensen MR, Wiesmann M, Kallen J, Furet P, Gessier F, Holzer P, Masuya K, Würthner J, Halilovic E, Hofmann F, Sellers WR, Graus Porta D
Publikováno v:
ELife [Elife] 2016 Nov 17; Vol. 5. Date of Electronic Publication: 2016 Nov 17.
Autor:
Fairhurst RA; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Switzerland. Electronic address: robin.fairhurst@novartis.com., Gerspacher M; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Switzerland., Imbach-Weese P; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Switzerland., Mah R; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Switzerland., Caravatti G; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Switzerland., Furet P; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Switzerland., Fritsch C; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Switzerland., Schnell C; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Switzerland., Blanz J; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Switzerland., Blasco F; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Switzerland., Desrayaud S; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Switzerland., Guthy DA; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Switzerland., Knapp M; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Switzerland., Arz D; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Switzerland., Wirth J; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Switzerland., Roehn-Carnemolla E; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Switzerland., Luu VH; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Switzerland.
Publikováno v:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2015 Sep 01; Vol. 25 (17), pp. 3575-81. Date of Electronic Publication: 2015 Jun 26.
Autor:
Gerspacher M; Novartis Institutes for BioMedical Research, Novartis Pharma AG, WKL-136.4.84, CH-4002 Basel, Switzerland. Electronic address: marc.gerspacher@novartis.com., Fairhurst RA; Novartis Institutes for BioMedical Research, Novartis Pharma AG, WKL-136.4.84, CH-4002 Basel, Switzerland., Mah R; Novartis Institutes for BioMedical Research, Novartis Pharma AG, WKL-136.4.84, CH-4002 Basel, Switzerland., Roehn-Carnemolla E; Novartis Institutes for BioMedical Research, Novartis Pharma AG, WKL-136.4.84, CH-4002 Basel, Switzerland., Furet P; Novartis Institutes for BioMedical Research, Novartis Pharma AG, WKL-136.4.84, CH-4002 Basel, Switzerland., Fritsch C; Novartis Institutes for BioMedical Research, Novartis Pharma AG, WKL-136.4.84, CH-4002 Basel, Switzerland., Guthy DA; Novartis Institutes for BioMedical Research, Novartis Pharma AG, WKL-136.4.84, CH-4002 Basel, Switzerland.
Publikováno v:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2015 Sep 01; Vol. 25 (17), pp. 3582-4. Date of Electronic Publication: 2015 Jun 30.
Autor:
Fairhurst RA; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Basel, Switzerland. Electronic address: robin.fairhurst@novartis.com., Imbach-Weese P; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Basel, Switzerland., Gerspacher M; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Basel, Switzerland., Caravatti G; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Basel, Switzerland., Furet P; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Basel, Switzerland., Zoller T; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Basel, Switzerland., Fritsch C; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Basel, Switzerland., Haasen D; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Basel, Switzerland., Trappe J; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Basel, Switzerland., Guthy DA; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Basel, Switzerland., Arz D; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Basel, Switzerland., Wirth J; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel, Basel, Switzerland.
Publikováno v:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2015 Sep 01; Vol. 25 (17), pp. 3569-74. Date of Electronic Publication: 2015 Jun 27.
A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
Autor:
Jeay S; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Gaulis S; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Ferretti S; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Bitter H; Disease Area Oncology, Novartis Institutes for BioMedical Research, Cambridge, United States., Ito M; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Valat T; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Murakami M; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Ruetz S; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Guthy DA; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Rynn C; Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research, Basel, Switzerland., Jensen MR; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Wiesmann M; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Kallen J; Center of Proteomic Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland., Furet P; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland., Gessier F; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland., Holzer P; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland., Masuya K; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland., Würthner J; Translational Clinical Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Halilovic E; Translational Clinical Oncology, Novartis Institutes for BioMedical Research, Cambridge, United States., Hofmann F; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Sellers WR; Disease Area Oncology, Novartis Institutes for BioMedical Research, Cambridge, United States., Graus Porta D; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Publikováno v:
ELife [Elife] 2015 May 12; Vol. 4. Date of Electronic Publication: 2015 May 12.
Autor:
Brachmann SM; NIBR Oncology Disease Area, Novartis Pharma AG, Basel CH4002, Switzerland. saskia.brachmann@novartis.com, Kleylein-Sohn J, Gaulis S, Kauffmann A, Blommers MJ, Kazic-Legueux M, Laborde L, Hattenberger M, Stauffer F, Vaxelaire J, Romanet V, Henry C, Murakami M, Guthy DA, Sterker D, Bergling S, Wilson C, Brümmendorf T, Fritsch C, Garcia-Echeverria C, Sellers WR, Hofmann F, Maira SM
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2012 Aug; Vol. 11 (8), pp. 1747-57. Date of Electronic Publication: 2012 May 31.